Symposium: Papers Presented at the Annual Meetings of The Hip Society

Clinical Orthopaedics and Related Research®

, Volume 471, Issue 2, pp 430-438

First online:

The Withdrawn ASR™ THA and Hip Resurfacing Systems: How Have Our Patients Fared Over 1 to 6 Years?

  • Kevin T. HugAffiliated withDepartment of Orthopaedic Surgery, Duke University Medical Center Email author 
  • , Tyler S. WattersAffiliated withDepartment of Orthopaedic Surgery, Duke University Medical Center
  • , Thomas P. VailAffiliated withDepartment of Orthopaedic Surgery, University of California, San Francisco
  • , Michael P. BolognesiAffiliated withDepartment of Orthopaedic Surgery, Duke University Medical Center

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Background

The Articular Surface Replacement™ (ASR™) metal-on-metal hip arthroplasty system (DePuy Orthopaedics, Inc, Warsaw, IN, USA) reportedly has a higher than anticipated early failure rate leading to a voluntary recall. This prompted us to evaluate all ASR™ components implanted at our center.

Questions/Purposes

In all ASR™ components, we reported (1) revision rate, (2) blood metal ion levels, and (3) intraoperative findings for revisions related to adverse reaction to metal debris (ARMD).

Methods

We retrospectively reviewed all 172 patients (190 hips) who underwent THA (149 hips) or hip resurfacing (41 hips) with the ASR™ system. We determined failure rates. We obtained blood metal ion concentrations from 93 patients at last followup. We evaluated MRI studies and intraoperative histopathology. Minimum followup was 12 months (mean, 40 months; range, 12–74 months).

Results

At latest followup, we had revised 24 of 190 hips (13%): in 18 patients with THA and five patients with resurfacing. Mean time to revision was 45 months (range, 12–75 months). Mean blood concentrations were 13 μg/L (range, 0–150 μg/L) for cobalt and 6 μg/L (range, 0–87 μg/L) for chromium. Mean prerevision blood metal ion levels were higher in the revised group (cobalt: 48 μg/L; chromium: 18 μg/L) than in the nonrevised group (cobalt: 5 μg/L; chromium: 2 μg/L). ARMD was present in 14 of the 24 hips revised in this study.

Conclusions

Surgeons must have a low threshold for concern for ARMD in patients with ASR™ systems. Blood metal ion levels and MRI can be used to evaluate patients with underperforming implants. Intraoperative histopathologic analysis and joint fluid cytology can help diagnose ARMD at the time of revision.

Level of Evidence

Level III, therapeutic study. See Instructions for Authors for a complete description of levels of evidence.